Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

From Clinical Trials to Real-World Practice: Surgical Feasibility and Postoperative Outcomes After Neoadjuvant Chemoimmunotherapy for Locally Advanced NSCLC in a Single-Center Experience.

Cancers·2026
Same author

Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer.

Cancer discovery·2026
Same author

Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

STHELAR, a multi-tissue dataset linking spatial transcriptomics and histology for cell type annotation.

Scientific data·2026

Related Experiment Video

Updated: Jul 1, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K

Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer.

Sabrina Rossi1, Arianna Pagliaro1,2, Giovanna Finocchiaro1

  • 1Medical Oncology & Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, 20089, Italy.

Future Oncology (London, England)
|March 6, 2024
PubMed
Summary

KRAS mutations may predict a better response to pembrolizumab in non-small-cell lung cancer patients receiving immunotherapy alone. This finding suggests KRAS status could guide treatment decisions for lung cancer.

Keywords:
KRASNSCLCcombination therapypembrolizumabpredictive factors

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.9K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Related Experiment Videos

Last Updated: Jul 1, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.9K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Area of Science:

  • Oncology
  • Genetics
  • Immunotherapy

Background:

  • Non-small-cell lung cancer (NSCLC) treatment landscape is evolving with immunotherapy.
  • Predictive biomarkers are crucial for optimizing patient selection for targeted therapies.
  • KRAS mutations are common in NSCLC but their role in predicting response to immunotherapy is under investigation.

Purpose of the Study:

  • To investigate the predictive value of KRAS mutations in NSCLC patients treated with first-line pembrolizumab.
  • To compare outcomes between KRAS-mutated and wild-type NSCLC patients receiving pembrolizumab monotherapy or chemo-immunotherapy.

Main Methods:

  • Retrospective analysis of NSCLC patients receiving first-line pembrolizumab.
  • Patients were categorized into pembrolizumab monotherapy (n=213) and chemo-immunotherapy (n=81) groups.
  • KRAS mutation status was assessed, and progression-free survival (PFS) and overall survival (OS) were analyzed.

Main Results:

  • KRAS mutations were identified in 27% of the study cohort.
  • In the pembrolizumab monotherapy group, KRAS-mutated NSCLC showed significantly longer PFS (11.3 vs 4.4 months, p=0.019).
  • No significant difference in PFS was observed in the chemo-immunotherapy group (9.7 vs 7.3 months, p=0.435).

Conclusions:

  • KRAS mutation status may serve as a predictive biomarker for response to pembrolizumab monotherapy in NSCLC.
  • Further research is warranted to elucidate the role of KRAS in chemo-immunotherapy response.